studies

urothelial cancer (UC) - bladder cancer (BC), avelumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsJAVELIN Bladder 100 (all population), 2020 0.69 [0.56; 0.86] JAVELIN Bladder 100 (PDL1>25%), 2020 0.56 [0.40; 0.79] 0.65[0.54; 0.78]JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 202023%1,058moderatenot evaluable deaths (OS) (extension)detailed resultsJAVELIN Bladder 100 (all population), 2020 0.76 [0.63; 0.92] JAVELIN Bladder 100 (PDL1>25%), 2020 0.69 [0.52; 0.91] 0.74[0.63; 0.86]JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 202020%1,058moderatenot evaluable PFS (extension)detailed resultsJAVELIN Bladder 100 (all population), 2020 0.54 [0.45; 0.64] JAVELIN Bladder 100 (PDL1>25%), 2020 0.46 [0.36; 0.59] 0.51[0.44; 0.59]JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 202029%1,058moderatenot evaluable progression or deaths (PFS)detailed resultsJAVELIN Bladder 100 (all population), 2020 0.62 [0.52; 0.74] JAVELIN Bladder 100 (PDL1>25%), 2020 0.56 [0.43; 0.73] 0.60[0.52; 0.70]JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 202020%1,058moderatenot evaluable DCRdetailed resultsJAVELIN Bladder 100 (all population), 2020 1.85 [1.35; 2.54] JAVELIN Bladder 100 (PDL1>25%), 2020 2.03 [1.31; 3.16] 1.91[1.48; 2.47]JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 202020%1,058moderatenot evaluable objective responses (ORR)detailed resultsJAVELIN Bladder 100 (all population), 2020 7.46 [2.53; 21.97] JAVELIN Bladder 100 (PDL1>25%), 2020 12.70 [2.11; 76.32] 8.59[3.41; 21.68]JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 202020%1,058moderatenot evaluable AE (any grade)detailed resultsJAVELIN Bladder 100 (all population), 2020 13.83 [6.28; 30.48] 13.83[6.28; 30.48]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 3.85 [2.72; 5.44] 3.85[2.72; 5.44]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable AE leading to death (grade 5)detailed resultsJAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68] 4.03[0.18; 89.68]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsJAVELIN Bladder 100 (all population), 2020 93.23 [5.71; 1522.42] 93.23[5.71; 1522.42]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable SAE (any grade)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.55 [1.09; 2.21] 1.55[1.09; 2.21]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable STRAE (any grade)detailed resultsJAVELIN Bladder 100 (all population), 2020 68.24 [4.16; 1120.28] 68.24[4.16; 1120.28]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable TRAE (any grade)detailed resultsJAVELIN Bladder 100 (all population), 2020 290.72 [105.09; 804.24] 290.72[105.09; 804.24]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 133.97 [8.24; 2178.15] 133.97[8.24; 2178.15]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable TRAE leading to death (grade 5)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsJAVELIN Bladder 100 (all population), 2020 73.11 [4.46; 1198.64] 73.11[4.46; 1198.64]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Arthritis TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Chills TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68] 4.03[0.18; 89.68]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Dry skin TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 20.63 [1.20; 354.60] 20.63[1.20; 354.60]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 6.06 [0.30; 121.47] 6.06[0.30; 121.47]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68] 4.03[0.18; 89.68]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Rash TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Uveitis TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Vitiligo TRAE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69] 1.00[0.02; 50.69]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Anaemia AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 1.32 [0.57; 3.04] 1.32[0.57; 3.04]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68] 4.03[0.18; 89.68]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Asthenia AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 0.12 [0.01; 2.36] 0.12[0.01; 2.36]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Back pain AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 0.50 [0.15; 1.66] 0.50[0.15; 1.66]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Constipation AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68] 4.03[0.18; 89.68]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Cough AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 0.50 [0.05; 5.54] 0.50[0.05; 5.54]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.18; 22.29] 2.01[0.18; 22.29]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Fatigue AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 3.04 [0.61; 15.19] 3.04[0.61; 15.19]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 6.06 [0.30; 121.47] 6.06[0.30; 121.47]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Nausea AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 0.50 [0.05; 5.54] 0.50[0.05; 5.54]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Pruritus AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Rash AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08] 2.01[0.07; 60.08]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable Vomiting AE (grade 3-4)detailed resultsJAVELIN Bladder 100 (all population), 2020 2.02 [0.37; 11.09] 2.02[0.37; 11.09]JAVELIN Bladder 100 (all population), 202010%689NAnot evaluable0.0500.01.0relative treatment effectwww.metaEvidence.org2024-05-28 08:43 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237 - treatments: 852,417,603,1051,876

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons